JUN 22, 2020 3:36 PM PDT

MDMA Has Long-Term Benefits Against PTSD

WRITTEN BY: Annie Lennon

Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-traumatic stress disorder (PTSD). 

The new paper explores the long-term outcomes for people a year after completing MDMA psychotherapies. Comprising follow-up data from six previous trials, all in all, the researchers gathered data on around 100 patients. 

Participants in each trial underwent two to three therapy sessions with active doses of MDMA (75-125mg) alongside additional regular psychotherapy sessions. Their PTSD symptoms were measured using the Clinician-Administered PTSD Scale for DSM IV at baseline either one or two months following their last MDMA session, and then at least 12 months after that. Each participant also filled in a long-term follow-up survey. 

At the first follow-up, the researchers noted that 56% of the cohort no longer met the clinical criteria for PTSD. However, after the second follow-up, they found that participants tended to continue to improve over the year. This meant that 12 months on from the MDMA-sessions, 67% of the cohort no longer met the criteria for PTSD. 

The researchers also noted that after treatment, patients tended to have fewer suicidal thoughts and general PTSD symptoms. Their data also suggested that MDMA therapy does not lead to MDMA abuse nor any other substance abuse. 

"These long-term follow-up findings show that once people with PTSD learn that they can productively process traumatic memories instead of suppressing them, they can continue to heal themselves even after they have stopped receiving MDMA-assisted psychotherapy," says Rick Doblin, one of the authors of the study. 

Following the success of these Phase II trials, MDMA-assisted therapy is now in Phase III human trials for severe, treatment-resistant PTSD, with US Food and Drug Administration (FDA) approval expected in 2022. 

Meanwhile, due to the effectiveness of the treatment, earlier this year, the FDA approved it for Expanded Access, allowing select patients to access the procedure before it has full-market approval. 


Sources: New Atlas, Springer,

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
MAY 04, 2021
Health & Medicine
Micro-dosing Inhaler Breakthrough for Medical Cannabis
MAY 04, 2021
Micro-dosing Inhaler Breakthrough for Medical Cannabis
In a leap that will eliminate the risks of vaping or smoking, Canada has just approved an Israeli-made inhaler that is a ...
MAY 11, 2021
Cardiology
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
MAY 11, 2021
Red Blood Cells Could Help Predict Recovery in Cardiovascular Patients
Cells are one of the basic building blocks of life. There are hundreds of different cell types, and they all work togeth ...
MAY 13, 2021
Health & Medicine
New Peptide Allows Cannabis to Fight Pain With Fewer Side Effects
MAY 13, 2021
New Peptide Allows Cannabis to Fight Pain With Fewer Side Effects
THC-rich cannabis is well known to bring relief for some chronic pain sufferers. But the downside, off putting for many ...
JUN 10, 2021
Cell & Molecular Biology
Does Lithium Prevent Colon Cancer?
JUN 10, 2021
Does Lithium Prevent Colon Cancer?
Researchers found that a drug used in the treatment of mental illness can promote the fitness of healthy gut stem cells, ...
JUN 24, 2021
Immunology
Should We Rethink COVID Vaccine Recipes?
JUN 24, 2021
Should We Rethink COVID Vaccine Recipes?
In a study reported in the journal Cell, immunologists provide evidence for an Achilles’ heel in current COVI ...
JUL 11, 2021
Drug Discovery & Development
Could Mucus-Based Drugs Replace Antibiotics?
JUL 11, 2021
Could Mucus-Based Drugs Replace Antibiotics?
Researchers from the Copenhagen Center for Glycomics in Denmark have developed a way to produce healthy mucus artificial ...
Loading Comments...